Answers are grounded in this paper and cite their sources.
Investigates bee products-derived extract's effect on allergic rhinitis symptoms, indicating a novel therapeutic approach.
Allergic rhinitis (AR) profoundly compromises physiological functions and diminishes human well-being. Current AR treatment strategies offer limited efficacy and significant side effects, underscoring the critical need for novel therapeutic approaches. In the present study, the potential therapeutic efficacy and underlying mechanism of a ternary bee products-derived extract mixture (PCH EM) were investigated in AR model. The characteristic symptoms of OVA-induced AR mouse were significantly alleviated after treatment with PCH EM, accompanied by reduced eosinophil infiltration in the submucosa and diminished goblet cell hyperplasia. Meanwhile, the administration of PCH EM significantly inhibited crucial systemic allergic mediators. Furthermore, caffeic acid phenethyl ester (CAPE) has been identified as an important component of PCH EM for inhibiting the mast cell degranulation and reducing the levels of key inflammatory mediators. Overall, these findings offer a valuable insights for PCH EM as a potential therapeutic strategy for AR and further functional food development.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: